Discovery of in vivo Chemical Probes for the Nervous System (R01 Clinical Trial Not Allowed)

Active
Yes
Status
Posted
Published Date
December 13th, 2023
Close Date
January 7th, 2027
Opportunity No.
PAR-24-088

Agency

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Summary

The National Institutes of Health (NIH) has posted a grant opportunity titled "Discovery of in vivo Chemical Probes for the Nervous System (R01 Clinical Trial Not Allowed)". This grant aims to support investigators in the discovery of in vivo chemical probes for novel brain targets. The purpose is to stimulate research in the development of small molecules for understanding biological processes relevant to the missions of the National Institute of Mental Health (NIMH), National Institute on Drug Abuse (NIDA), National Eye Institute (NEI), and/or National Institute on Aging (NIA). Additionally, the grant seeks to discover and validate novel biological targets that will inform studies of brain disease mechanisms. Projects that provide new insight into important disease-related biological targets and processes will be given emphasis. The grant does not require cost sharing or matching. The eligible applicants include various institutions and organizations such as Alaska Native and Native Hawaiian Serving Institutions, Faith-based or Community-based Organizations, and U.S. Territories or Possessions. The closing date for this grant opportunity is January 7, 2027. For more information and to apply, visit the following link: Discovery of in vivo Chemical Probes for the Nervous System Grant. For any inquiries, contact NIH Grants Information at grantsinfo@nih.gov.

Description

The purpose of this Notice of Funding Opportunities (NOFOs) is to support investigators who have interest and capability to join efforts for the discovery of in vivo chemical probes for novel brain targets. It is expected that applicants will have, in hand, the starting compounds (validated hits) for chemical optimization and bioassays for testing new analog compounds. Through this NOFO, NIH wishes to stimulate research in 1) discovery and development of novel, small molecules for their potential use in understanding biological processes relevant to the missions of National Institute of Mental Health (NIMH), National Institute on Drug Abuse (NIDA), National Eye Institute (NEI), and/or National Institute on Aging (NIA) and 2) discovery and/or validation of novel, biological targets that will inform studies of brain disease mechanisms. Emphasis will be placed on projects that provide new insight into important disease-related biological targets and biological processes.

Contact Information

Attachments
0 KB

Opportunity Lifecycle

Title
Type
Grant

Similar Opportunities

Drug Discovery For Nervous System Disorders (R01 Clinical Trials Not Allowed)
National Institutes of Health
The National Institutes of Health is offering a grant opportunity titled "Drug Discovery For Nervous System Disorders (R01 Clinical Trials Not Allowed)". This grant aims to support the discovery of novel compounds for the prevention and treatment of nervous system disorders. The grant encourages research in various areas, including the identification, design, synthesis, and preclinical testing of compounds for candidate therapeutics, initial hit-to-lead chemistry, later stage lead optimization, and initial drug metabolism and pharmacokinetic (DMPK) studies. Projects that provide innovative approaches for identifying potential therapeutic agents will be given priority. The grant does not require cost sharing or matching. The eligible applicants include various institutions and organizations, such as Alaska Native and Native Hawaiian Serving Institutions, Faith-based or Community-based Organizations, and U.S. Territories or Possessions. The deadline for application submission is January 7, 2025. For more information and to apply, please visit the following link: [Drug Discovery For Nervous System Disorders Grant](http://grants.nih.gov/grants/guide/pa-files/PAR-22-031.html).
Drug Discovery For Nervous System Disorders (R21 Clinical Trials Not Allowed)
National Institutes of Health
The National Institutes of Health is offering a grant opportunity titled "Drug Discovery For Nervous System Disorders (R21 Clinical Trials Not Allowed)". This grant aims to support the discovery of novel compounds for the prevention and treatment of nervous system disorders. The grant encourages research in various areas, including the identification, design, synthesis, and preclinical testing of compounds for candidate therapeutics, as well as hit-to-lead chemistry, lead optimization, and drug metabolism and pharmacokinetic studies. Projects that provide innovative approaches for identifying potential therapeutic agents will be given priority. The grant does not require cost sharing or matching. The maximum award ceiling is $275,000. The deadline for applications is January 7, 2025. For more information and to apply, visit the following link: [http://grants.nih.gov/grants/guide/pa-files/PAR-22-032.html](http://grants.nih.gov/grants/guide/pa-files/PAR-22-032.html). For any inquiries, contact NIH OER Webmaster at OERWebmaster03@od.nih.gov.
Assay Development and Screening for Discovery of Validated Chemical Hits for Brain Disorders (R01 Clinical Trial Not Allowed)
National Institutes of Health
The National Institutes of Health is offering a grant opportunity titled "Assay Development and Screening for Discovery of Validated Chemical Hits for Brain Disorders (R01 Clinical Trial Not Allowed)". This grant aims to stimulate research in the discovery and development of novel, small molecules for studying disease treatment relevant to psychiatric disorders. It also aims to generate new insight into the biology of relevant diseases and processes that have yet to be validated as important drug targets. The grant does not require cost sharing or matching. The funding instrument type is a grant, and the category of funding activity is health. The eligible applicants include various institutions and organizations such as Alaska Native and Native Hawaiian Serving Institutions, Faith-based or Community-based Organizations, and U.S. Territories or Possessions. The closing date for this grant opportunity is May 7, 2026. For more information and to apply, visit the following link: [Assay Development and Screening for Discovery of Validated Chemical Hits for Brain Disorders Grant](http://grants.nih.gov/grants/guide/pa-files/PAR-23-168.html). For any inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
Engineering Next-Generation Human Nervous System Microphysiological Systems (R01 Clinical Trials Not Allowed)
National Institutes of Health
The National Institutes of Health is offering a grant opportunity titled "Engineering Next-Generation Human Nervous System Microphysiological Systems (R01 Clinical Trials Not Allowed)". This grant aims to support research projects focused on developing advanced human cell-derived microphysiological systems (MPS) and related assays. The goal is to create systems that replicate complex nervous system architectures and physiology with improved accuracy compared to current capabilities. These systems will enable future studies on the development, function, and aging of the nervous system in both healthy and disease states. The grant does not require cost sharing or matching. The eligible applicants include various institutions and organizations such as Alaska Native and Native Hawaiian Serving Institutions, Faith-based or Community-based Organizations, and U.S. Territories or Possessions. The closing date for applications is January 7, 2026. For more information and to apply, visit the following link: [http://grants.nih.gov/grants/guide/pa-files/PAR-23-046.html](http://grants.nih.gov/grants/guide/pa-files/PAR-23-046.html). For any inquiries, contact NIH Grants Information at grantsinfo@nih.gov.